Table 1.

Baseline patient characteristics.

	Nabiximols-placebo	Placebo-nabiximols	Total*
	N = 17	N = 17	N = 34
Gender
Male	10 (59%)	14 (82%)	24 (71%)
Female	7 (41%)	3 (18%)	10 (29%)
Age (y)	65 (58–73)	69 (61–71)	68 (59–72)
Stroke type
Hemorrhagic	7 (41%)	6 (35%)	13 (38%)
Ischemic	10 (59%)	11 (65%)	21 (62%)
Affected side
Right	6 (35%)	7 (41%)	13 (38%)
Left	11 (65%)	10 (59%)	21 (62%)
Time after stroke (y)	2.6 (1.3–4.9)	4.9 (2.7–10.1)	4.2 (1.7–5.6)

^*Patients who completed the study (both phase 1 and phase 2). Values are reported as number (%) or median (Q1–Q3).